CRISPR Gene Therapy for Sickle Cell Is Now Approved for Young Children
On 2 July 2026, the FDA expanded the CRISPR gene therapy Casgevy to children as young as two with sickle cell disease or transfusion-dependent beta thalassemia — offering a one-time treatment before years of cumulative damage set in.